First Wave BioPharma, Inc. Banner Image

First Wave BioPharma, Inc.

  • Ticker FWBI
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
First Wave BioPharma, Inc. Logo Image
  • 1-10 Employees
  • Based in Boca Raton, Florida
First Wave BioPharma, Inc. (formerly AzurRx BioPharma) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. First Wave is currently advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies – niclosamide, an oralMore small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. First Wave’s niclosamide portfolio is led by three clinical programs: FW-COV, for COVID-19 gastrointestinal infections; FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis; and FW-ICI-AC, for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-associated colitis and diarrhea in advanced oncology patients. Two additional formulations of niclosamide, FW-UC (ulcerative colitis) and FW-CD (Crohn’s disease) are expected to enter the clinic in 2022 and 2023, respectively.
4.8 / 5.0 (123)

First Wave BioPharma, Inc. reports have an aggregate usefulness score of 4.8 based on 123 reviews.

First Wave BioPharma, Inc.

Most Recent Annual Report

First Wave BioPharma, Inc.
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

First Wave BioPharma, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!